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InfectivityTo establish PrPSc-speciﬁc mAbs, we immunized Prnp-/- mice with PrPSc puriﬁed from prion-infected mice.
Using this approach, we obtained mAb 6H10, which reacted with PrPSc treated with proteinase K, but not
with PrPSc pretreated with more than 3 M GdnHCl. In contrast, reactivity of pan-PrP mAbs increased with
increasing concentrations of GdnHCl used for pretreatment of PrPSc. In histoblot analysis, mAb 6H10 showed
a positive reaction on a non-denatured histoblot but reactivity was lower when the histoblot was pretreated
by autoclaving. Epitope analysis suggested that the extreme C-terminus of PrP is likely to be part of the
epitope for mAb 6H10. MAb 6H10 immunoprecipitated PrPSc from brains of mice, sheep, and cattle infected
with prions. Furthermore, pretreatment of puriﬁed PrPSc with mAb 6H10 reduced the infectious titer more
than 1 log. Taken together, these results suggest that mAb 6H10 recognizes a conformational epitope on
PrPSc that is related to prion infectivity.
© 2009 Elsevier Inc. All rights reserved.Introduction
Prion diseases are fatal neurodegenerative diseases which include
scrapie in sheep and goats, bovine spongiform encephalopathy (BSE),
and Creutzfeldt-Jakob diseases (CJD) in humans. A hallmark of the
diseases is the accumulation of a pathogenic, abnormal isoform of
prion protein, designated PrPSc, in the central nervous system of
affected animals. PrPSc is generated from the host-encoded, cellular
prion protein, PrPC, by certain post-translational modiﬁcation includ-
ing conformational transformation (Prusiner et al., 1998). Although
the two isoforms are encoded by the host gene, PrP, they differ from
each other biochemically and biophysically. For example, PrPC is
soluble in non-ionic detergents and sensitive to protease treatment,
whereas PrPSc is insoluble due to its propensity to form aggregates
that are partially resistant to protease treatment (Oesch et al., 1985;
Meyer et al., 1986). PrPC has a high α-helix but low β-sheet content,
whereas PrPSc has a higher β-sheet content (Caughey et al., 1991; Pan
et al., 1993; Safar et al., 1993). However, PrPSc is comprised of PK-
sensitive and PK-resistant PrPSc, such that PrPSc cannot be distin-
guished from PrPC simply using protease treatment (Bessen and
Marsh, 1994; Safar et al., 1998, 2005; Silveira et al., 2005).Horiuchi).
ll rights reserved.To date, there have been a number of reports on the production of
monoclonal and polyclonal antibodies against PrP molecules. Most of
these are pan-PrP antibodies that recognize either linear or discontin-
uous epitopes on PrPC and react with PrPSc pretreated with denaturant
(Kascsak et al., 1987; Serban et al., 1990; Williamson et al., 1996;
Peretz et al., 1997; Kim et al., 2004a). Because of the co-existence of
PrPC and PrPSc, and the propensity of PrPSc to form aggregates, removal
of PrPC by protease treatment and subsequent denaturation are
prerequisites for speciﬁc detection of PrPSc by pan-PrP antibodies.
However, the ability to analyze the properties of PrPSc using pan-PrP
antibodies is limited, as the biological and biochemical properties of
PrPSc are affected by protease treatment and denaturation.
Molecular probes that speciﬁcally react to PrPSc and distinguish
PrPSc from PrPC can be a powerful tool for analysis of the entity of
PrPSc. For instance, PrPC will be act as a molecular probe for PrPSc, as
PrPC binds to PrPSc (Horiuchi et al., 1999). A fusion protein comprised
of PrPC and the immunoglobulin Fc region and a genetically modiﬁed
antibody possessing PrPC segments have been demonstrated to bind
to PrPSc possibly via the PrPC segments (Meier et al., 2003; Moroncini
et al., 2004). Moreover, plasminogen binds to PrPSc not to PrPC;
however, plasminogen will bind to other serum proteins and thus,
selectivity of the binding is obscure (Fischer et al., 2000). In contrast to
many reports of pan-PrP mAbs, only a few studies have reported anti-
PrPSc antibodies that speciﬁcally discriminate PrPSc from PrPC (Korth
Fig. 1. Reactivity of mAb 6H10 to PrPSc in ELISA. (a) Reactivity to PK-treated PrPSc. Wells
were coatedwith 200 ng/well of puriﬁed, PK-untreated PrPSc of the Obihiro strain. After
adsorption, wells were treated with the indicated concentrations of PK. After
terminating PK activity with Pefabloc, the wells were subjected to the antibody
reaction. The anti-PrP mAbs used were 6H10, 31C6, 72, and 44B1. Anti-KLH mAb was
used as a negative control mAb. (b) Effect of denaturation of PrPSc. Puriﬁed PrPSc
adsorbed to the wells was digested with 20 μg/ml PK and treated with GdnHCl (0–6M)
at r.t. for 1 h. Then wells were subjected to the antibody reaction.
Fig. 2. Reactivity of mAb 6H10 to PrPSc in Immunoblotting. (a) Reactivity of mAbs 6H10
and 31C6 on an immunoblot. PK-treated (+) and PK-untreated (-) brain homogenates
of mice infected with the Obihiro strain were subjected to immunoblotting. (b)
Immunoprecipitation. PK-digested puriﬁed PrPSc of the Obihiro strain in PBS containing
1% Triton X-100 was incubated with antibodies as indicated at the top. The antigen–
antibody complexes were collected with magnetic beads coated with protein G. PrPSc in
precipitates (ppt) and supernatants (sup) were detected by immunoblotting using
HRP-conjugated mAb 31C6. Anti-KLH mAb (KLH) was used as a negative control mAb.
PK-digested PrPSc fractions at 50 and 20 μg brain equivalents were loaded as controls.
201M. Horiuchi et al. / Virology 394 (2009) 200–207et al., 1997; Paramithiotis et al., 2003; Curin Serbec et al., 2004; Jones
et al., 2009).
Availability of a panel of PrPSc-speciﬁc antibodies is indispensable
for analysis of the biochemical properties of PrPSc. Thus, in order to
obtain PrPSc-speciﬁc antibodies, we immunized PrP-ablated (Prnp-/-)
mice with PrPSc puriﬁed from prion-infected mouse brains. Prion
infectivity is thought to be associated with PrPSc oligomers; thus, we
used non-denatured, puriﬁed PrPSc as the immunogen. One of the
mAbs, clone 6H10, showed interesting reactivity to PrP molecules;
mAb 6H10 reacted with non-denatured PrPSc but not with recombi-
nant mouse PrP (rMoPrP) or denatured PrPSc in an enzyme-linked
immunosorbent assay. This pattern of reactivity implied that mAb
6H10 recognizes PrPSc but not PrPC, allowing for detailed character-
ization of mAb 6H10.
Results
Reactivity of mAb 6H10 to puriﬁed PrPSc
To obtain PrPSc-speciﬁc mAbs, we immunized Prnp-/- mice with a
puriﬁed PrPSc fraction and hybridoma supernatants were screened
with the puriﬁed PrPSc and rMoPrP by enzyme-linked immunosorbent
assay (ELISA). We established one mAb, 6H10 (isotype: IgG2b), which
reacted with puriﬁed PrPSc but not with rMoPrP or PrPSc denatured
with 6 M GdnHCl. This pattern of reactivity suggests that mAb 6H10
might speciﬁcally recognize the PrPSc conformation and thus, we
further analyzed mAb 6H10.
Figure 1 shows reactivity of mAb 6H10 and pan-PrP mAbs to
puriﬁed PrPSc. The mAbs 31C6, 44B1, and 72, which were character-
ized as pan-PrP mAbs, reacted with puriﬁed PrPSc before proteinase K
(PK) treatment (0 μg/ml), but reactivity disappeared when PrPSc was
pretreated with 20 μg/ml or higher concentrations of PK (Fig. 1a). It is
known that PrPSc forms sedimentable aggregates, and PrPC or
protease-sensitive PrP molecules, which are expected to expose the
epitopes for pan-PrP mAbs, are usually co-puriﬁed with PrPSc during
puriﬁcation. Thus, the drastic decline in reactivity of pan-PrP mAbs
with increases in PK concentration is probably due to removal of
protease-sensitive PrP species from the puriﬁed PrPSc fraction. In
contrast to the results of pan-PrP mAbs, mAb 6H10 reacted with PrPSc
treated with up to 320 μg/ml of PK (Fig. 1a).
Most of epitopes for pan-PrP mAbs are buried in aggregates of
puriﬁed PrPSc, and become exposed as denaturation reveals cryptic
epitopes (Kim et al., 2004a). In contrast, PrPSc-speciﬁc conformational
epitope(s), if they exist, would be expected to be destroyed upon
denaturation. Consistent with this, reactivity of mAb 6H10 gradually
decreased and disappeared when PK-treated PrPSc was treated with
more than 3 M GdnHCl (Fig. 1b). This is different from pan-PrP mAbs,
which did not react with PK-treated PrPSc without denaturation (at 0
M GdnHCl) but reactivity became apparent and increased as the
GdnHCl concentration is increased (Fig. 1b). Taken together, the
results suggested that mAb 6H10 recognizes a conformational epitope
on PrPSc. Consistent with this, mAb 6H10 did not react with PrPSc in
immunoblot analysis (Fig. 2a). To conﬁrm reactivity of mAb 6H10 to
PrPSc, we performed immunoprecipitation analysis. The mAb 6H10
precipitated PrPSc into the bead-bound fraction from a suspension of a
puriﬁed PrPSc fraction, whereas most of PrPSc remained in the
unbound fraction in the case of mAb 31C6 or a negative control
mAb (Fig. 2b). Following immunoprecipitation of PrPSc by mAb 6H10,
the amount of PrPSc that remained in the corresponding supernatant
was decreased.
Immunoprecipitation of PrPSc from brain homogenates by mAb 6H10
Next we performed immunoprecipitation from brain homoge-
nates. The mAb 31C6 immunoprecipitated bands corresponding to
PrPC from brain homogenates of uninfected mouse, whereas mAb6H10 did not. PrP precipitated from brain homogenates of mice
infected with the Obihiro or Chandler strain by mAb 31C6 dis-
appeared after PK treatment. In contrast, 6–7 kDa smaller PrP bands
were detected when fractions immunoprecipitated from brain
Fig. 3. Immunoprecipitation of PrPSc by mAb 6H10. Brain homogenates (2.5%) of prion-infected or uninfected animals were incubated with 10 μg of mAbs (6H10, 31C6, P2-168) and
then immunoprecipitatedwith protein G coupledmagnetic beads. Bead-bound fractionswere treatedwith PK [PK(+)] or not [PK(-)] and then subjected to immunoblotting. The blots
were probed with HRP-conjugated mAb 31C6. MAb P2-168 was used as a negative control mAb. Homo, brain homogenates of uninfected mice or mice infected with prions.
Fig. 4. Reactivity of mAb 6H10 to non-infectious PrP aggregates. (a) Immunoprecip-
itation of non-aggregated rMoPrP89-231 (S) and aggregated rMoPrP89-231 (P) with
mAbs 31C6, 6H10, and P2-168. The mAb P2-168 is an isotype-matched negative control
for mAb 6H10. Samples were prepared as described in Materials andMethods, and 10 μl
of bead-bound fraction was loaded in each lane. The blot was probed with HRP-
conjugated mAb 44B1. (b) After chemiluminescence reaction, the same blot in (a) was
washed with PBST and re-probed with HRP-conjugated goat anti-mouse Igs (GE
Healthcare) to ensure comparable amount of mAbs were used for each immunopre-
cipitation. Closed and open arrowhead indicate immunoglobulin heavy and light chain,
respectively. Arrow indicates rMoPrP89-231 detected in the re-probing process.
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mAb 6H10 were treated with PK (Fig. 3). Thus, at least, some fraction
of the PrP immunoprecipitated with mAb 6H10 was resistant to PK
treatment. These results suggest that mAb 6H10 selectively recog-
nizes an epitope speciﬁc to PrPSc and thus has a potential to
distinguish PrPSc from PrPC. Moreover, mAb 6H10 exhibited broad
host speciﬁcity; the mAb reacted with PrPSc in the brains of scrapie-
affected sheep and BSE-affected cattle (Fig. 3). These results suggest
that, if not all, at least a certain population of PrPSc in the brains of
prion-infected animals possesses the epitope for mAb 6H10 on its
surface.
Recently, Biasini et al. (2008) reported that mAb 15B3, which is
purported to be speciﬁc to PrPSc (Korth et al., 1997), also reacted with
non-infectious PrP aggregates. Thus we analyzed reactivity of mAb
6H10 to PrP aggregates prepared from rMoPrP89-231 puriﬁed from
Escherichia coli (Fig. 4). The mAb 31C6 immunoprecipitated both
non-aggregated and aggregated rMoPrP89-231. In contrast, mAb
6H10 did not immunoprecipitate non-aggregated rMoPrP89-231, but
showed weak reaction to aggregated rMoPrP89-231 at the same level
as an isotype-matched negative control (mAb P2-168). Thus, the
reaction of mAb 6H10 to aggregated rMoPrP89-231 appears to be a
non-speciﬁc reaction that is possibly caused by a hydrophobic
property of aggregated rMoPrP89-231. The same results were
obtained when rMoPrP23-231 was used (data not shown). Consid-
ering that mAb P2-168 did not immunoprecipitate PrPSc from brains
of prion-infected animals, again, the reactivity of mAb 6H10 to PrPSc in
immunoprecipitation is thought to be a speciﬁc reaction between
mAb 6H10 and the epitope on PrPSc.
Reactivity of mAb 6H10 to prion-infected and uninfected brain
in histoblot
To further analyze the reactivity of mAb 6H10 to PrPSc, we
performed histoblot analysis (Fig. 5a). Two pan-PrP anitbodies, one of
which is antiserum of Prnp-/- mice immunized with rMoPrP (NIAH),
and the other is mAb 110, showed positive reaction to histoblot of
prion-infected and uninfected mouse brains. However, the positive
signals nearly disappeared when the blots were pretreated with PK,
indicating that the signals represented protease-sensitive PrP. When
the PK-treated histoblots were further processed by autoclaving,
which partially denatures PrPSc and thus exposes cryptic epitopes,
these antibodies reacted only with prion-infected mouse brains. In
contrast, mAb 6H10 reacted intensely to a histoblot of prion-infectedmouse brain pretreated with PK and the intensity was drastically
reduced by autoclaving of the histoblot. These results indicated that
PrPSc accumulated in the brain possessed the epitope for mAb 6H10.
Unexpectedly, mAb 6H10 showed weak reaction to PK-untreated,
uninfected mouse brain sample, although the reaction was not
observed on a PK-treated histoblot. To examine whether mAb 6H10
reacts not only with PrPSc but also PrPC in a histoblot, we used brains
of wild-type (Prnp+/+) and Prnp-/- mice. The mAb 44B1, classiﬁed as
pan-PrP mAb, reacted only with the brain of Prnp+/+ mice as
expected. However, mAb 6H10 reacted weakly with both Prnp+/+
and Prnp-/- mice brains (Fig. 5b). Thus, the weak reaction of mAb
6H10 to the brains of uninfected mice may be the result of the
presence of a host antigen(s) other than PrPC that shares an epitope
similar to that for mAb 6H10.
Fig. 5. Histoblot analysis. (a) Cryosections of Obihiro strain-infected (Inf) and
uninfected mice brains (Uninf) were blotted onto PVDF membranes. The histoblots
on the 1st row were neither treated with autoclave (AC-) nor PK (PK-). The blots on the
2nd row were treated with 50 μg/ml PK (PK+) but not with autoclave (AC-), and those
on the 3rd row were treated with PK (PK+) and then autoclaved (AC+). Antibodies:
KLH, negative control mAb; NIAH, serum of Prnp-/- mouse immunized with rMoPrP;
110, mAb 110; 6H10, mAb 6H10. (b) Histoblots of wild-type (Prnp+/+) and Prnp-/-
mouse brains were stained with antibodies as indicated.
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Next, we examined whether mAb 6H10 can neutralize prion
infectivity. Puriﬁed PrPSc from mice infected with the Obihiro strain
was pre-incubated with mAbs and then inoculated intracerebrally to
mice for a bioassay (Table 1). Pre-incubation of PrPSc with mAb 6H10
prolonged the mean incubation time by 19 days compared to PrPScTable 1
Neutralization of prion infectivity by mAb 6H10.




Anti-KLH 5 5 161±4
mAb 31C6 5 5 166±6
mAb 110 5 5 169±7
mAb 6H10 5 5 180±8a
Brain homogenateb
10% 10 10 161±6
1% 12 12 164±6
0.1% 12 12 175±6
0.01% 11 11 189±18
0.001% 12 12 212±12
0.0001% 11 11 245±31
0.00001% 6 3 278±52
0.000001% 6 0 N393
a pb0.01 by ANOVA followed by Dunnett's post hoc test.
b To obtain an infectivity–incubation time standard curve, 10-fold serial dilutions of
brain homogenates of mice infected with the Obihiro strain were bioassayed. The 50%
lethal dose (LD50) of the original homogenates (10% brain homogenates) was estimated
to be 106 LD50/20 μl by the Reed-Muench method. The standard curve for incubation
periods (x) shorter than 190 days was ﬁtted by the approximation of LD50=e41.48 - 0.183x.
The standard curve for incubation periods (x) longer than 190 days was ﬁtted by the
approximation of LD50=e21.07 - 0.076x.pretreated with negative control mAbs anti-KLH (pb0.01), whereas
pre-treatment with mAb 31C6 or 110 appeared to prolong the
incubation time a little but the differences were not signiﬁcant. A
prolongation of 19 days was inferred as corresponding to a more than
95% reduction in prion infectivity based on the infectivity–incubation
time standard curve obtained from bioassays of serially diluted brain
homogenates from the Obihiro strain-infected mice (Table 1). Several
pan-PrPmAbs have been reported to inhibit the accumulation of PrPSc
in prion persistently infected neuroblastoma cells when the cells were
incubated with those mAbs (Enari et al., 2001; Peretz et al., 2001;
Perrier et al., 2004; Kim et al., 2004b). Cells persistently infected with
the Obihiro strain were unavailable so far, we used mouse
neuroblastoma cells persistently infected with the Chandler strain
(I3/I5-9 cells, Kim et al., 2004b) to examine whether mAb 6H10
inhibits PrPSc formation in cells. Cells were cultured with mAb 6H10
(up to 20 μg/ml) for 4 days; however, mAb 6H10 did not affect the
PrPSc formation in I3/I5-9 (data not shown). Our previous study
showed that anti-PrP mAbs strongly reacted with PrPC on the cell
surface could inhibit PrPSc formation in I3/I5-9 cells (Kim et al.,
2004b). However, mAb 6H10 did not react with cell surface of I3/I5-9
cells by ﬂowcytometirc analysis (data not shown).
Epitope for mAb 6H10
To investigate the epitope for mAb 6H10, we adopted phage
display analysis. Fig. 5a shows consensus amino acid (aa) residues
deduced from selected phage clones with mAbs 31C6 or 110, or rabbit
polyclonal antibodies (pAb) B103. Three or four aa residues of the
phage clones selected with mAbs 31C6 and 110 were identical to the
aa residues in regions determined by pepspots analysis (Kim et al.,
2004a). Similarly, three or four aa residues of selected phage clones
with pAb B103 were identical to the synthetic peptide used as the
immunogen. These results suggest that at least three residues are
required to form an epitope for antibody. In total, 56 phage clones
selected after ﬁve rounds of panning with mAb 6H10, and these were
subjected to DNA sequencing so that the aa sequences could be
deduced. The consensus aa residues of two abundant phage clones are
listed in Fig. 6a. The most abundant phage clone ph#121 contained
four residues identical to the C-terminus of MoPrP (SPSQAWLYMRHE,
underlined residues). The secondmost abundant phage clone ph#125
also had three residues identical to the C-terminus of MoPrP
(TQNWSMSMLLKQ, underlined residues). In contrast, no aa sequence
identity to MoPrP was observed in the third most abundant phage
clone ph#98 (IPLTGKYLDEQS, 6/56, 11%). Binding of antibodies to
selected phage clones was conﬁrmed by captured ELISA (Fig. 6b). The
mAb 6H10 reacted with phage clones ph#121 and ph#125, originally
selected by mAb 6H10, but not with ph#6, originally selected by mAb
31C6. On the other hand, mAb 31C6 reacted only with phage clone
ph#6. Taken together, these data demonstrate the speciﬁcity of phage
clone selection. Moreover, the results suggest that the C-terminus of
MoPrP is involved in the formation of the epitope for mAb 6H10. We
also analyzed the epitope for mAb 6H10 using a pepspots membrane;
however, mAb 6H10 did not react with any spots (data not shown).
Discussion
Immunization of Prnp-/- mice and screening of hybridomas with
non-denatured PrPSc is one of the ways to establish PrPSc-speciﬁc
mAbs. Using this approach, we obtained mAb 6H10, which reacted
with non-denatured PrPSc but not with denatured PrPSc. It is well
known that epitopes for pan-PrP antibodies on PrPSc become
accessible by antibodies after dissociation of PrPSc aggregates and/or
denaturation of PrPSc (Kascsak et al., 1987; Serban et al., 1990;
Williamson et al., 1996). However, the reactivity of mAb 6H10 to PrPSc
decreased with the increases in GdnHCl concentration for the
pretreatment of PrPSc to 3 M, indicating that the properties of mAb
Fig. 6. Epitope analysis by peptide phage display. (a) Identity of aa sequences between selected phage clones and the region to which antibodies are expected to bind. The aa
sequence of the epitopes of mAbs 110 and 31C6 were determined by pepspots analysis (Kim et al., 2004a), whereas that of pAb B103 corresponds the synthetic peptide used for
immunization (Horiuchi et al., 1995). The deduced aa sequences indicate that consensus aa residues of selected phage clones. Shown are two abundant consensus sequences
deduced from selected phage clones, which were obtained after three rounds (for pAb B103, andmAbs 110 and 31C6) or ﬁve rounds (for mAb 6H10) of panning. Amino acid residues
identical to the expected region are indicated in bold. Numbers in parentheses indicate the total number of phage clones analyzed for each antibody (denominators) and the
numbers of phage clones that possess the corresponding consensus aa sequence (numerators). The residues that are expected to constitute the epitope for each antibody are
underlined (possible epitope). (b) Binding of antibodies to selected phage clones. Wells coated with mAb 6H10 or 31C6 were incubated with four-fold serial dilutions of the selected
phage clones (ph#121, ph#125, or ph#6). Phage–antibody complexes were detected as described in Materials and Methods. Phage clones ph#121 and ph#125, selected by mAb
6H10, express the peptides SPSQAWLYMRHE and TQNWSMSMLLKQ, respectively. Phage ph#6, selected by mAb 31C6, expresses peptide SDWHTRFHYSMN (underlining indicates
the consensus aa residues for the corresponding epitope).
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strain, which was used as a source of PrPSc in this study, was
dramatically reduced by the treatment with 3 M GdnHCl (Shindoh
et al., 2009), consistent with a decrease in the reactivity of mAb 6H10
to PrPSc of the Obihiro strain pretreated with 3 M GdnHCl.
Furthermore, mAb 6H10 neutralized infectivity of PrPSc puriﬁed
frommice infected with the Obihiro strain (Table 1). Thus, mAb 6H10
may recognize a conformational epitope on non-denatured PrPSc that
is related to the oligomerization interface on the PrPSc molecule.
Reduction of the hydrophobic surface on PrPSc correlated with the
dissociation and/or denaturation of PrPSc by GdnHCl at concentra-
tions between 0 and 3 M (Safar et al., 1994). Circular dichroism
analysis also revealed that GdnHCl dissociated PrPSc aggregates with
a midpoint of transition around 2 M (Safar et al., 1993). The half-
maximal GdnHCl concentrations, which are required to denature 50%
of PrPSc, have been reported to range from 1.5 to 3 M for most of
mouse-adapted scrapie and BSE prions (Legname et al., 2006;
Shindoh et al., 2009). In addition, treatment of samples with 2–4 M
GdnHCl resulted in decrease of prion infectivity (Caughey et al., 1997;
McKenzie et al., 1998). Although these reports used different prion
strains, the decrease in reactivity of mAb 6H10 to PrPSc with an
increase in GdnHCl concentration for pretreatment of PrPSc concurs
with structural alteration of PrPSc or the decrease of infectivity
induced by GdnHCl at similar concentrations.
The results of phage display analysis suggested the possibility that
the extreme C-terminus of PrP molecule is part of the epitope for mAb
6H10. Among the amino acid residues expected to compose the
epitope for mAb 6H10 (aa215-TQxxxxSQAxxxxR-aa228 of MoPrP),
the underlined residues are identical to those of sheep and bovine PrP.
This may be consistent with the fact that mAb 6H10 could
immunoprecipitate PrPSc from sheep and cattle samples. The mAb6H10 showed no reaction with denatured PrPSc by immunoblotting or
ELISA (Figs. 1 and 2), or with the corresponding C-terminal peptide by
pepspots analysis (data not shown). In contrast, reactivity of mAbs
that recognize linear epitopes on the extreme C-terminus increased
after pretreatment of PrPSc with denaturants (Peretz et al., 1997; Kim
et al., 2004a). Thus it is unlikely that mAb 6H10 binds linear epitope
composed of the C-terminal residues. One mAb, V5B2, which was
raised against a synthetic peptide corresponding to the C-terminal
residues of human PrP (aa214-CITQYERESQAYY-aa226), is reported to
discriminate PrPSc in brains of CJD patients from PrPC in non-CJD
brains possibly by recognizing the oligomerized C-terminal region in
PrPSc oligomers (Curin Serbec et al., 2004; Ulrih et al., 2006).
Therefore, the C-terminal regions of two PrPmoleculesmay cooperate
to form a conformational epitope; however, the exact properties of
the epitope for 6H10 are not yet fully elucidated. Alternatively, in the
proposed model of PrPSc protoﬁbrils, the C-terminal region is thought
to be located in close proximity to other regions on the same or
different PrP molecule (DeMarco and Daggett, 2004; Govaerts et al.,
2004). Cross-linking of recombinant PrP oligomers revealed that an
interaction between the N- and C-terminal regions (Kaimann et al.,
2008). Thus, the C-terminal region and other regions on the same or
different PrP molecule may participate in constituting the epitope for
mAb 6H10. The mAb 15B3, which was produced by immunizing
recombinant bovine PrP and is purported to be speciﬁc to PrPSc,
reacted with three PrP segments, residues 141–147, 161–269, and
213–215 of MoPrP in pepspots analysis (Korth et al., 1997).
Involvement of the extreme C-terminus in the epitope for mAb
15B3 is intriguing; however, mAb 6H10 did not react with any PrP
peptides in pepspots analysis (data not shown). Thus, the epitope for
mAb 6H10 seems to differ from that for mAb 15B3. Recently, mAb
15B3 is reported to react with infectious and non-infectious PrP
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of mAb 6H10 to aggregated rMoPrP (Fig. 4). Although a weak non-
speciﬁc reaction to aggregated rMoPrP was observed, mAb 6H10 did
not show any speciﬁc reaction to aggregated rMoPrP, suggesting mAb
6H10 is more speciﬁc to PrPSc generated in brains of prion-infected
animals.
Some mAbs against either PrP or non-PrP molecules have been
reported to immunoprecipitate PrPSc via an epitope-independent
reaction when mAbs were bound to a solid phase such as magnetic
beads, as binding of immunoglobulins on the limited area of the solid
surface increases the concentration of immunoglobulins in that area
and thus a low-afﬁnity interaction between PrPSc and immunoglobu-
lins on the beads may occur (Morel et al., 2004). We considered that
this possibility is unlikely in the case of mAb 6H10 for several reasons.
First, bead-free mAb 6H10 reacted with PrPSc in ELISA and histoblot
analysis (Figs. 1 and 5). In addition, a direct interaction of ﬂuorescent
dye-labeled mAb 6H10 with non-denatured PrPSc in brain homo-
genates of mice infected with prions can be detected in solution by
ﬂuorescent correlation spectroscopy (K. S. and M.H., in preparation).
Secondly, a Fab' fragment of mAb 6H10 still reacted with native
puriﬁed PrPSc in ELISA (data not shown). However, a weak non-
speciﬁc reaction to aggregated rMoPrP would be expected depending
on experimental conditions (Fig. 4), careful experimental design, such
as the use of negative control mAb and comparison between prion-
infected and mock-infected materials, will be required to ensure
speciﬁc reactivity of mAb 6H10 to PrPSc.
The reactivity of mAb 6H10 to PrPSc in biochemical analysis
strongly suggests that mAb 6H10 discriminates PrPSc from PrPC.
However, in histoblot analysis, the mAb showed weak reaction to
certain host molecule in Prnp-/- mice. This raises two possibilities.
First, the mAb may recognize a host molecule other than PrP with an
epitope similar to that for mAb 6H10 on PrPSc. The presence of third
abundant phage clone (ph#98) that selected by mAb 6H10, aa
sequence of which showed no apparent homology to PrP, may clue
the identiﬁcation of such host molecule. However, no protein or
peptide domain was found by homology search using protein blast
and tblastn or domain search using Conserved Domain Database.
Secondly, the mAb may recognize a host factor tightly associated with
PrPSc in the prion-infected mouse brain, rather than reacting with
PrPSc itself. The latter possibility suggests that the positive reaction to
PK-treated PrPSc in ELISA was due to a reaction to a PK-resistant
molecule tightly associated with PrPSc, which seems unlikely because
the PrPSc fraction used in this study was estimated to be nearly 90%
pure after PK treatment (Kim et al., 2004a). However, this possibility
cannot be completely ruled out at present, particularly as several
macromolecules, including glycosaminoglycans (Snow et al., 1989),
ubiquitin (Lowe et al., 1990), apolipoprotein E (Namba et al., 1991)
have been shown to co-localize with PrPSc in brains of prion-infected
animals and human. In addition, nucleic acids (Aiken et al., 1990;
Sklaviadis et al., 1993) and sphingolipid (Klein et al., 1998) have been
co-puriﬁed with PrPSc.
In this study, we showed the possibility that the C-terminal region
forms a PrPSc-speciﬁc epitope. Recently, immunization of β-form
recombinant human PrP could induce production of mAbs that react
with the N-terminal region of PrPSc (aa91–110; Khalili-Shirazi et al.,
2007). The immunization of aggregated synthetic peptide
corresponding to aa106–126 of PrP also generated a mAb that
discriminates PrPSc from PrPC (Jones et al., 2009). These results
suggest that PrPSc-speciﬁc epitopes are present at various regions on
PrPSc. A fusion protein of PrP and Fc-region of immunoglobulin and
PrP-peptide-grafted antibodies have been reported to recognize PrPSc
(Meier et al., 2003; Moroncini et al., 2004, 2006; Solforosi et al., 2007;
Lau et al., 2007). In addition, there are nucleotide aptamers that
possess higher afﬁnity to PrPSc than to PrPC (Rhie et al., 2003), and
small chemicals such as 9-aminoacridine, streptomycin, luminescent
conjugated polymers, polyionic polymers Seprion (Microsens bio-technologies) and others, may also act as PrPSc-speciﬁc probes
(Moussa et al., 2006; Phuan et al., 2007; Sigurdson et al., 2007).
Despite technical difﬁculties in manipulating PrPSc due to its
aggregation-prone propensity and heterogeneity, PrPSc-speciﬁc mo-
lecular probes are gradually accumulating. As the availability of a
panel of anti-PrP mAbs has greatly contributed to characterization of
the biochemical properties of PrP, a panel of PrPSc-speciﬁc molecular
probes appears to be indispensable tools for analyzing the biochem-
ical and biological properties of native PrPSc with which prion
infectivity is believed to be associated.
Materials and methods
Puriﬁcation of PrPSc and production of mAbs
The puriﬁcation PrPSc from brains of mice infected with prion
Obihiro strain and purity of PrPSc were reported elsewhere (Kim et al.,
2004a). Immunization of PrPSc and production of mAbs were carried
out as described (Kim et al., 2004a).
Antibodies
The followingmAbs against mouse PrP molecules were used: 31C6
(IgG1, epitope: aa 143–149), 44B1 (IgG 2a, epitope: aa 155–231), 72
(IgG1, epitope: aa 89–231), and 110 (IgG2b, epitope: aa 59–89) (Kim
et al., 2004a). Anti-keyhole limpet hemocyanin (KLH) mAb (IgG2a)
and anti-parvovirus mAb P2-168 (IgG2b) (Horiuchi et al., 1997) were
used as negative controls. Rabbit antiserum raised against bovine PrP
synthetic peptide 103-121 (pAb B103) was also used (Horiuchi et al.,
1995). Puriﬁcation of mAbs was carried out as described elsewhere
(Kim et al., 2004a). Conjugation of mAbs with horseradish peroxidase
(HRP) was carried out as follows: puriﬁed mAbs were digested with
pepsin and reduced by 2-mercapthoethanolamine (MEA) to generate
Fab' fragments. After removal of MEA with a PD-10 size exclusion
column (GE Healthcare), the Fab' fragments were mixed with HRP
coupled with the bi-directional cross-linker GMBS (Dojin).
ELISA
Ninety-six well plates (MaxiSorp, Nunc) were coated overnight at
4 °C with either 200 ng puriﬁed PrPSc or 100 ng rMoPrP in 50 μl of
20 mM phosphate buffer (pH 7.0). After adsorption, wells were
blocked with 5% fetal bovine serum (FBS) in PBS containing 0.1%
Tween 20 (PBST) for 2 h at room temperature (r.t.), and incubated
with antibodies diluted with 1% FBS in PBST for 1 h. After washing
with PBST, wells were incubated with HRP-conjugated secondary
antibodies for 1 h. The antigen–antibody complexes were visualized
with 2,2′-azino-bis(3-etht-benzthiazoline-6-sulfonic acid), 0.04%
H2O2 in 50 mM citrate–phosphate buffer, pH 4.0, and the absorbance
at 405 nm was measured with a microplate reader. In some cases,
PrPSc adsorbed to the well was digested with various concentrations
of proteinase K (PK) in Tris-buffered saline (TBS; 50 mM Tris–HCl [pH
8.0] and 150 mM NaCl) at 37 °C for 45 min. After terminating PK
activity by adding Pefabloc (Roche Diagnostic) to a ﬁnal concentration
at 2 mM, the plates were subjected to the immune reaction.
Immunoblotting
SDS-PAGE and immunoblotting of proteins on an Immobilon-P
Transfer Membrane (Millipore) were carried out as described
elsewhere (Kim et al., 2004a, 2004b). Membranes were blocked
with 5% skim milk in PBST for 1 h and then incubated with HRP-
conjugated Fab fragment of anti-PrP mAbs (direct staining) or anti-
PrP mAb followed by incubation with HRP-conjugated secondary
antibodies (indirect staining). ECL Western blotting detection
reagents (GE Healthcare) and X-ray ﬁlm were used for visualization.
206 M. Horiuchi et al. / Virology 394 (2009) 200–207Immunoprecipitation
Protein G-coupled magnetic beads (Dynabeads) were blocked
with blocking buffer containing 5% skim milk and 50% Sea Block
(Pierce) in PBS. Brain homogenates (2.5%) from prion-infected or
uninfected animals were prepared with PBS containing 0.5% I-Block
(Applied Biosystem), and were incubated with 10 μg of mAb and
protein G magnetic beads for 45 min at 37 °C. The magnetic beads
were washed four times with PBS containing 2% Triton X-100 using a
magnetic separator. After washing, the beads were suspended with
50 μl of TBS and divided into two tubes. An equal volume of 2 sample
buffer (8 M urea, 10% SDS, 8% b-mercaptoethanol, 125 mM Tris–HCl
[pH 6.8], 6 mM EDTA, 10% glycerol, and 0.04% bromophenol blue) was
added to one tube to make samples without PK treatment. The other
was treated with 40 μg/ml of PK for 30 min at 37 °C. The reaction with
PK was stopped with 2 mM Pefabloc before adding 2 sample buffer.
To examine the reactivity of mAbs to non-infectious PrP
aggregates, rMoPrP23-231 or rMoPrP89-231 (Kim et al., 2004a)
were diluted to 20 μg/ml with 1 ml of 1% Triton-X 100 in PBS (PBS-
Triton, pH 7.2) and kept for 30 min at 20 °C. Then samples were
centrifuged at 100,000×g for 45 min at 20 °C. The supernatant was
recovered and used as non-aggregated rMoPrP, while the resulting
precipitate was resuspended with 1 ml of PBS-Triton by sonication
and used as aggregated rMoPrP. Protein G-coupled magnetic beads
(100 μl) were incubated with 20 μg of mAbs and then blocked with 5%
skim milk and 5% N102 blocking reagent (NOF Corporation, Japan) in
PBS-Triton for 1 h at r.t. After washing with PBS-Triton once, the beads
were mixed with 300 μl of non-aggregated or aggregated rMoPrP for
45min at r.t. The beads were washed four times with 1ml of 2% Triton
X-100 in PBS and ﬁnally washed with PBS. Proteins bound to the
magnetic beads were eluted with 100 μl of 1× sample buffer.
Histoblot analysis
Histoblot analysis was carried out as described by Taraboulos et
al. (1992). Immobilon-P Transfer Membranes were activated with
methanol and then equilibrated with lysis buffer (0.5% Nonidet P-40,
0.5% sodium deoxycholate, 100 mM NaCl, 10 mM EDTA, 10 mM Tris–
HCl [pH 7.8]). Mouse brain cryosections (8 μm) were prepared and
placed on glass slides. The glass slides carrying the sections were
immediately pressed onto membranes on layers of ﬁlter paper
saturated with lysis buffer for 1 min. The membranes were
thoroughly air-dried and stored at -80 °C until use. Before
immunostaining, the membranes were rehydrated in PBST for 1
h at r.t. and then immunostaining was carried out as described above
for immunoblotting.
Neutralization of prion infectivity
Fifteen micrograms of puriﬁed PrPSc were incubated with 36 μg of
mAb in 300 μl of PBS containing 0.1% Zwittergent 3–12 for 2 h at r.t.
The mixture (20 μl) containing 1 μg PrPSc was then inoculated
intracerebrally into 4-week-old female slc:ICR mice. For dose–
infectivity correlation, 20 μl each of serially diluted brain homo-
genates from mice infected with the Obihiro strain were inoculated
intracerebrally to 4-week-old female slc:ICR mice.
Peptide phage display
The Ph.D.-12™ Phage Display Library Kit (New England Biolabs), a
combinatorial library which expresses random 12-mer-peptides at
the N-terminus of a minor coat protein of M13 phage, was used
according to the supplier's instructions. Polystyrene Petri dishes
(60×15 mm) were coated overnight at 4 °C with 1.5 ml of 100 μg/ml
antibodies in 0.1 M NaHCO3 (pH 8.6). After blocking with 0.5% FBS in
PBS for 1 h, dishes were rinsed six times with PBST and theninoculated with 4×1010 of the phage library. After 1 h incubation at r.
t., the dishes were washed 10 times with PBS and then bound phage
was eluted by addition of 1 ml 0.2 M glycine–HCl (pH 2.2) for 10 min.
The eluate was immediately neutralized with 150 μl of 1 M Tris–HCl
(pH 9.1). In total, 1 ml of the eluate was used for ampliﬁcation of the
selected phage pool and the ampliﬁed phage stock was subsequently
used for the next panning.
After three to ﬁve rounds of panning, phage DNA encoding the
selected random peptide sequences was ampliﬁed directly from
individual plaques by PCR using primers PD12F (5′-TCAAGCTGTT-
TAAGAAATTCACC-3′) and PD12R (5′-TAAAGTTTTGTCGTCTTTCCA-
GAC-3′). The PCR products were puriﬁed by S-300 HR spin column
(GE Healthcare) and used as templates for DNA sequencing. DNA
sequences were determined with an automated DNA sequencer (ABI-
373A, Applied Biosystems) and using the ABI PRISM Dye Terminator
Cycle Sequencing Ready Reaction Kit.
Binding of antibodies to selected peptides was conﬁrmed by a
captured ELISA. Brieﬂy, 96-well plates coated with antibodies (20 ng/
well) were incubated with four-fold serial dilutions of the phage stock
for 1 h at r.t. After washing with PBST, plates were incubated with
HRP-conjugated anti-M13 antibody to detect the phage captured by
the antibodies. Phage–antibody complexes were detected as de-
scribed for ELISA.
Pepspots analysis
Pepspots analysis was carried out as described elsewhere (Kim et al.,
2004a).
Statistical analysis
Statistical analysis was donewith JMP software (SAS Institute Inc.).
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